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Abstract 
Synovial sarcomas (SS) account for 5–10% of soft-tissue sarcomas and typically arise in the para-articular regions of adolescents and 
young adults. Nonetheless, SS can occasionally occur in other regions of the body. Here, we present a first clinical literature report of a 
patient with an SS arising from the vaginal wall. A 40-year-old patient who presented a necrotic polypoid lesion, measuring 50 mm and 
extending from the external urethral meatus to the middle part of the anterior vaginal wall. The biopsy showed a poorly differentiated SS 
with abundant necrosis and a SYT-SSX1 mutation. A staging CT scan was negative for distant metastases. The patient, prior to the 
radical surgery, received neoadjuvant chemotherapy (ifosfamide and epirubicin) for three cycles. She underwent post-operative external 
radiotherapy and brachytherapy (50 Gy) due to close margins (<1 mm) in the pathologic specimen. She relapsed 11 and 16 months later 
with lung metastases, which, both times, were successfully removed by surgical resection. At 24 months from diagnosis, the patient is 
alive without further evidence of disease. In summary, in the presence of unfavourable prognostic factors, neoadjuvant chemotherapy 
could be the primary approach to reduce the tumour size and the risk of distant micro-metastases allowing a less aggressive radical 
surgery if the tumour is located in a non-extremity site. Hence, a multidisciplinary approach, if not influencing overall survival and 
disease-free survival, may improve the quality of life. In fact, in our patient we obtained a complete clinical control in the pelvis, avoiding 
pelvic exenteration with neoadjuvant chemotherapy. 
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Background 
Synovial sarcomas account for 5–10% of soft-tissue sarcomas, 
which typically arise in the para-articular regions of adolescents 
and young adults. Nonetheless, SS rarely occur in the 
mediastinum head and neck region, heart, lung and 
retroperitoneum. Here, we present a clinical literature report of a 
patient with a synovial sarcoma arising from the vaginal wall. 
The immunohistochemical, molecular and ultrastructural details 
of this case have been previously reported [1].  
 
Case presentation 
A 40-year-old patient was referred to the European Institute of 
Oncology (Milan, Italy) with a diagnosis, from elsewhere, of a 
high-grade vaginal leiomyosarcoma. She was severely anaemic 
due to abnormal vaginal bleeding, and pelvic examination 
revealed a necrotic, friable and bluish polypoid lesion, 
measuring 50 mm longitudinally and extending from the external 
urethral meatus to the middle part of the anterior vaginal wall. A 
staging CT scan was negative for distant metastases.  
Histopathological review of the original sections revealed a 
poorly differentiated synovial sarcoma, and the patient was 
treated with neoadjuvant chemotherapy, including high-dose 
ifosfamide (9 g/m
2) and epirubicin (90 mg/m
2), q 21 days, for 
three cycles, obtaining a partial clinical response (tumour size 
by clinical examination: 1 cm). She then underwent wide local 
excision of the anterior vaginal wall, with preservation of the 
external urethral meatus. 
The pathology report confirmed the diagnosis of a poorly 
differentiated synovial sarcoma and the patient received post-
operative external radiotherapy and brachytherapy (50 Gy) for 
close margins (<1 mm). 
Eleven months later the patient experienced three metastases 
to the right lung, which were treated with wedge resection. Five 
months later, three other metastases were found on the 
contralateral lung and were successfully removed by surgical 
resection. 
At 25 months from diagnosis, the patient is alive without further 
evidence of pulmonary or other metastases or local recurrence. 
Pathological and molecular findings  
Microscopic examination of this case revealed a high-grade, 
biphasic, poorly differentiated synovial sarcoma with abundant 
necrosis and mitoses (more than 10/10 high-power fields). The 
immunohistochemical findings were consistent with the 
diagnosis of a poorly differentiated synovial sarcoma, arising 
from the vaginal wall. 
The rearrangement of the SYT gene, characteristic of SS, was 
detected confirming the diagnosis of synovial sarcoma. A 
reverse transcriptase-polymerase chain reaction assay revealed 
a SYT-SSX1 fusion gene product of 158 bp. 
  
Discussion 
Synovial sarcomas constitute approximately 5–10% of all soft-
tissue sarcomas [2]. Although 90% of cases are diagnosed in 
the extremities and occur before the age of 50 years, they may 
arise in a wide variety of organs, including head and neck area, 
mediastinum, heart, lung, abdominal wall, mesentery, 
retroperitoneum and peritoneal cavity [3]. In the female genital 
tract, the occurrence of synovial sarcomas is extremely rare, 
and only isolated case reports have been described in the 
fallopian tube, [4] the vulva [5–7] and the vagina [8]. 
The chance of a synovial sarcoma occurring in other body 
locations apart from the extremities is supported by the 
hypothesis that they do not arise from synovial tissue. In fact, it 
has been suggested that they originate from unknown stem 
cells that are capable of differentiating into mesenchymal and/or 
epithelial structures (an hypothesis that still needs to be 
confirmed) [9]. Biphasic synovial sarcomas contain both 
epithelial cells arranged in glandular structures and spindle 
cells, whereas monophasic types are entirely composed of 
spindle cells. On the other hand, the poorly differentiated type, 
as the one reported here, often contain small round cells 
resembling those seen in Ewing's primitive neuroectodermal 
tumours. However, only immunohistological, ultrastructural and 
cytogenetic features allow correct diagnosis. 
Other types of synovial sarcoma include leiomyosarcoma 
(which account for the most common histology in any single 
tumour series of the vagina), the spindle cell variant of 
squamous cell carcinoma and the rare mixed tumour of the 
vagina, either benign or malignant. 
Synovial sarcomas are characterized by the presence a specific 
genetic translocation, the SYT-SSX translocation t(X;18) 
(p11.2;q11.2), which represents a specific diagnostic marker, 
being present in 95% of all SS cases. Its presence, as the only 
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cytogenetic abnormality, suggests that it is the primary cause of 
synovial sarcoma. 
There are several subtypes, numbered SYT-SSX 1, 2 and 4 
[10,11], and these genetic subtypes are correlated with 
histological subtypes and clinical behaviour. Biphasic synovial 
sarcomas are associated with the presence of the SYT-SSX1 
mutation, while monophasic synovial sarcomas are correlated 
with the mutation SYT-SSX2. There are data that indicate that a 
particular subtype of translocation has prognostic significance. 
In two studies, the SYT-SSX 2 translocation was primarily 
associated with the monophasic histotype and a better outlook 
for survival five years after diagnosis, compared with the SYT-
SSX 1 translocation, which was primarily associated with 
biphasic disease and a worse outlook for five-year survival 
[10,11]. 
An essential first step in the successful treatment of synovial 
sarcoma is adequate surgical resection with tumour-free 
surgical margins [12–14]. 
However, in cases with unfavourable localization such as the 
head and neck, retroperitoneum, chest and female genital tract, 
chemotherapy and, perhaps, pre-operative radiation therapy 
should be initially given, with the aim of reducing the tumour 
volume, thus facilitating surgical resection. Our patient received 
primary chemotherapy with epirubicin and ifosfamide, with good 
partial remission. Other active regimens can include vincristine, 
actinomycin D and cyclophosphamide (VAC). 
It is interesting to point out that the combination of doxorubicin 
and ifosfamide induced a more significant responses compared 
to VAC regimens, as described in two other studies [15,16]. 
After surgery, our patient received 50 Gy of radiotherapy, as the 
tumour margins were close (<1 mm) in the pathologic specimen. 
Given sarcoma's relative rarity, the precise doses of 
radiotherapy to achieve local control in microscopic and gross 
residual disease categories are not well known. However, 
Raney et al [17] usually propose to use a dose of 55 Gy for 
microscopic or recurrent disease after surgical removal, and 
somewhat higher, about 60 Gy, in the presence of visible 
residual tumour. 
The natural course of the disease is such that many patients will 
experience recurrence of the primary tumour and/or metastatic 
disease. The reported five-year overall survival rates range from 
38% to 76% [18,19]
  and from 20% to 63% in ten years [19,20] . 
As synovial sarcomas can grow slowly, the ten or 20-year 
survival rates are more accurate. In fact Paulino [21] found that 
approximately 26% of distant relapses occurred after five years 
from the initial diagnosis and 2% were diagnosed 15 years after 
the initial diagnosis. Metastatic disease occurs in almost 50% of 
patients. The most common site of metastasis is the lungs (74–
81%), lymph nodes (3–23%) and bone (10–20%) [22-24].   
The unfavourable prognostic factors, described in several 
studies, include a tumour size more than 5 cm, tumour 
localization in a non-extremity site, primary treatment outside a 
referral centre, a patient age of more than 25 years, the 
presence of tumour necrosis areas and bone invasion [13,25] 
and the presence of a particular SYT-SSX translocation (SYT-
SSX1) [10]. However, the strongest prognostic factor associated 
with local recurrence, metastases and tumour-related death in a 
multivariate analysis [25] is the presence and the amount 
of poorly differentiated areas within the tumour. 
Our patient was more than 25 years old, had a tumour of more 
than 5 cm with abundant necrosis and poorly differentiated 
histology, a non-extremity site location and an SYT-SSX1 
mutation. All these factors indicate an unfavourable prognostic 
outcome and can probably explain the aggressive behaviour of 
the tumour. 
In summary, in the presence of unfavourable prognostic factors, 
neoadjuvant chemotherapy could be the primary approach to 
reduce the tumour size and the risk of distant micro-metastases 
and allowing a less aggressive radical surgery if the tumour is 
located in a non-extremity site. Hence, a multidisciplinary 
approach, even if having no influence on overall survival and 
disease-free survival, may improve the quality of life. In fact, in 
our patient we obtained complete clinical control in the pelvis 
with neoadjuvant chemotherapy, so avoiding pelvic 
exenteration. 
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